Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients

Authors

• Susannia Ibrahim, Regional Public Hospital of Sumedang, Sumedang, West Java, IndonesiaFollow
• Ajeng Diantini, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, West Java, Indonesia
• Budhi Prihartanto, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, West Java, Indonesia
• Rudi Supriyadi, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Jatinangor, West Java, Indonesia

Abstract

Chronic renal failure (CRF) is one the most prevalent health problems among the elderly. On
the fifth stage of CRF, the patient becomes eligible to hemodialysis. CRF-induced anemia
is commonly treated with Erythropoietin (Epo). Information regarding the effectiveness of
Epo in hypertensive hemodialysis patients was limited. Therefore, this study was conducted
to evaluate the effectiveness of Epo in hypertensive hemodialysis patients. This study used
an observational case-control analytic method. Data were retrieved from the medical records
of hemodialysis patients during March-May 2014. A total of 54 participants were included.
The increase of haemoglobin (Hb) in controlled hypertension was 0.6257 g/dl, while the in
uncontrolled hypertension group, there was a decrease in Hb (-0.1590 g/dl). The use of Epo
was more effective in hemodialysis patients with controlled hypertension.

Recommended Citation

Ibrahim, Susannia; Diantini, Ajeng; Prihartanto, Budhi; and Supriyadi, Rudi (2017) "Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients," Pharmacology and Clinical Pharmacy Research: Vol. 2: Iss. 2, Article 2.
DOI: 10.15416/pcpr.v2i2.15245
Available at: https://journal.unpad.ac.id/pcpr/vol2/iss2/2